Inhibition of TLR3 by famotidine decreases IL-6 (Mukherjee et al., 2021) and reduces the risk of intubation and death in patients hospitalized with COVID-19 and alleviates symptoms in non-hospitalized patients with COVID-19 (Mather et al., 2020). This evidence concerns the gene TLR3 and COVID-19.